Studie - Endometriosis – Pipeline Review, H1 2012

Endometriosis — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Endometriosis - Pipeline Review, H1 2012', provides an overview of the Endometriosis therapeutic pipeline. This report provides information on the therapeutic development for Endometriosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometriosis. 'Endometriosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Endometriosis.
- A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Endometriosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Endometriosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Endometriosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Endometriosis Overview 8

Therapeutics Development 9

An Overview of Pipeline Products for Endometriosis 9

Endometriosis Therapeutics under Development by Companies 11

Mid Clinical Stage Products 13

Comparative Analysis 13

Early Clinical Stage Products 14

Comparative Analysis 14

Pre-Clinical Stage Products 15

Comparative Analysis 15

Endometriosis Therapeutics — Products under Development by Companies 16

Companies Involved in Endometriosis Therapeutics Development 17

Abbott Laboratories 17

Euroscreen S.A. 18

Takeda Pharmaceutical Company Limited 19

Astellas Pharma Inc. 20

Kissei Pharmaceutical Co., Ltd. 21

Addex Pharmaceuticals 22

AEterna Zentaris Inc. 23

Soligenix, Inc. 24

Repros Therapeutics Inc. 25

Peptron, Inc. 26

Meditrina Pharmaceuticals, Inc. 27

PregLem SA 28

Isifer AB 29

Endometriosis — Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

AEZS-115 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

TAK-385 - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Elagolix - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ADX68692 - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

GnRH Antagonists - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Proellex - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

LPM Leuprolide - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Drugs For Prostate Cancer & Endometriosis - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

PGL2001 - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ESN-364 - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

MPI-676 - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

KLH-2109 - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ASP1707 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Endole - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Endometriosis Therapeutics — Drug Profile Updates 52

Endometriosis Therapeutics — Discontinued Products 57

Endometriosis Therapeutics - Dormant Products 58

Endometriosis — Product Development Milestones 60

Featured News & Press Releases 60

Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids 60

Jan 03, 2012: Repros Completes Dosing In Phase II Low-Dose Oral Proellex Trial 61

Nov 03, 2011: ValiRx Files New Patent For VAL201 For Further Indication In Endometriosis 62

Oct 04, 2011: Neurocrine Receives Second Milestone Payment Of $20m Under Abbott Collaboration Agreement 63

Sep 27, 2011: Neurocrine Announces Elagolix Scientific Presentations At 67th Annual Meeting Of American Society For Reproductive Medicine 63

Sep 20, 2011: Repros Commences Dosing Of Last Cohort In Oral Proellex Low Dose Study 64

Aug 29, 2011: Takeda Initiates Phase II Clinical Trials Of TAK-385 In Japan 64

Jun 23, 2011: Repros Enrolls Fourth Cohort In Low Dose Proellex Study 65

Jun 16, 2011: Neurocrine Announces Elagolix Scientific Presentations At 11th World Congress On Endometriosis 65

Mar 15, 2011: Repros Therapeutics Reports Results From Completed 1mg Dose Cohort In Low Dose Proellex Study 66

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 69

Contact Us 69

Disclaimer 69





List of Tables

Number of Products Under Development for Endometriosis, H1 2012 9

Products under Development for Endometriosis — Comparative Analysis, H1 2012 10

Number of Products under Development by Companies, H1 2012 12

Comparative Analysis by Mid Clinical Stage Development, H1 2012 13

Comparative Analysis by Early Clinical Stage Development, H1 2012 14

Comparative Analysis by Pre-Clinical Stage Development, H1 2012 15

Products under Development by Companies, H1 2012 16

Abbott Laboratories, H1 2012 17

Euroscreen S.A., H1 2012 18

Takeda Pharmaceutical Company Limited, H1 2012 19

Astellas Pharma Inc., H1 2012 20

Kissei Pharmaceutical Co., Ltd., H1 2012 21

Addex Pharmaceuticals, H1 2012 22

AEterna Zentaris Inc., H1 2012 23

Soligenix, Inc., H1 2012 24

Repros Therapeutics Inc., H1 2012 25

Peptron, Inc., H1 2012 26

Meditrina Pharmaceuticals, Inc., H1 2012 27

PregLem SA, H1 2012 28

Isifer AB, H1 2012 29

Assessment by Monotherapy Products, H1 2012 30

Assessment by Stage and Route of Administration, H1 2012 32

Assessment by Stage and Molecule Type, H1 2012 34

Endometriosis Therapeutics — Drug Profile Updates 52

Endometriosis Therapeutics — Discontinued Products 57

Endometriosis Therapeutics — Dormant Products 58

Endometriosis Therapeutics — Dormant Products (Contd..1) 59





List of Figures

Number of Products under Development for Endometriosis, H1 2012 9

Products under Development for Endometriosis — Comparative Analysis, H1 2012 10

Products under Development by Companies, H1 2012 11

Mid Clinical Stage Products, H1 2012 13

Early Clinical Stage Products, H1 2012 14

Pre-Clinical Stage Products, H1 2012 15

Assessment by Monotherapy Products, H1 2012 30

Assessment by Route of Administration, H1 2012 31

Assessment by Stage and Route of Administration, H1 2012 32

Assessment by Molecule Type, H1 2012 33

Assessment by Stage and Molecule Type, H1 2012 34

• Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
• Cervical Dysplasia – Pipeline Review, H1 2013
• EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
• Female Sexual Dysfunction – Pipeline Review, H1 2013
• Menopausal Disorders – Pipeline Review, H1 2013
• Menopausal Hot Flashes – Pipeline Review, H1 2013
• Uterine Fibroids – Pipeline Review, H1 2013
• Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013
• Dysmenorrhea – Pipeline Review, H1 2013
• Endometriosis – Pipeline Review, H1 2013
• Women Infertility – Pipeline Review, H1 2013
• Premature Labor (Tocolysis) – Pipeline Review, H2 2012
• Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012
• Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
• Premature Ovarian Failure – Pipeline Review, H2 2012
• Premenstrual Syndrome – Pipeline Review, H2 2012
• Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy
• Endometriosis Global Clinical Trials Review, H2, 2012
• Primary Dysmenorrhea – Pipeline Review, H2 2012